- Report
- January 2022
- 117 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- August 2019
- 30 Pages
China
From €2123EUR$2,200USD£1,821GBP
- Report
- January 2019
- 30 Pages
China
From €2123EUR$2,200USD£1,821GBP
- Report
- December 2018
- 30 Pages
China
From €2123EUR$2,200USD£1,821GBP
- Report
- December 2022
- 79 Pages
North America
From €1448EUR$1,500USD£1,242GBP
- Report
- April 2024
- 50 Pages
Global
From €2558EUR$2,650USD£2,194GBP
Follitropin Beta is a type of sexual and reproductive health drug used to treat infertility in women. It is a recombinant form of follicle-stimulating hormone (FSH) that helps to stimulate the growth of ovarian follicles in women who are unable to produce eggs naturally. Follitropin Beta is administered through subcutaneous injection and is used in combination with other fertility treatments such as in vitro fertilization (IVF).
Follitropin Beta is used to treat infertility in women who have not responded to other treatments, such as clomiphene citrate or gonadotropin-releasing hormone (GnRH) agonists. It is also used to treat women with polycystic ovary syndrome (PCOS) and women who have had their ovaries removed.
The Follitropin Beta market is a growing segment of the sexual and reproductive health drugs market. It is expected to experience steady growth in the coming years due to increasing awareness of infertility treatments and the rising prevalence of infertility.
Some companies in the Follitropin Beta market include Merck, Ferring Pharmaceuticals, Teva Pharmaceuticals, and Pfizer. Show Less Read more
